These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 3291592)
1. Cellular mechanisms in congestive heart failure. Katz AM Am J Cardiol; 1988 Jul; 62(2):3A-8A. PubMed ID: 3291592 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms and abnormalities of contractility and relaxation in the failing heart. Katz AM Cardiologia; 1993 Dec; 38(12 Suppl 1):39-43. PubMed ID: 8020041 [TBL] [Abstract][Full Text] [Related]
3. The myocardium in congestive heart failure. Katz AM Am J Cardiol; 1989 Jan; 63(2):12A-16A. PubMed ID: 2521266 [TBL] [Abstract][Full Text] [Related]
4. Energetics and the failing heart. Katz AM Hosp Pract (Off Ed); 1991 Aug; 26(8):78-90. PubMed ID: 1869612 [TBL] [Abstract][Full Text] [Related]
5. Energy requirements of contraction and relaxation: implications for inotropic stimulation of the failing heart. Katz AM Basic Res Cardiol; 1989; 84 Suppl 1():47-53. PubMed ID: 2530976 [TBL] [Abstract][Full Text] [Related]
6. The heart in congestive failure. Katz AM Cardioscience; 1990 Mar; 1(1):3-6. PubMed ID: 2151711 [TBL] [Abstract][Full Text] [Related]
8. Are inotropic agents contraindicated in congestive heart failure? Katz AM Cardiovasc Drugs Ther; 1989 Jan; 2(6):747-50. PubMed ID: 2488087 [TBL] [Abstract][Full Text] [Related]
9. Inotropic and lusitropic abnormalities in heart failure. Katz AM Eur Heart J; 1990 Apr; 11 Suppl A():27-31. PubMed ID: 2344853 [TBL] [Abstract][Full Text] [Related]
10. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Katz AM Circulation; 1986 Mar; 73(3 Pt 2):III184-90. PubMed ID: 2417747 [TBL] [Abstract][Full Text] [Related]
11. Energetic consequences of substances currently used or recommended for long-term treatment of chronic heart failure. Holubarsch C; Hasenfuss G; Thierfelder L; Just H Basic Res Cardiol; 1991; 86 Suppl 1():107-12. PubMed ID: 1827977 [TBL] [Abstract][Full Text] [Related]
12. Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options. Hamilton DJ Methodist Debakey Cardiovasc J; 2017; 13(1):25-28. PubMed ID: 28413579 [TBL] [Abstract][Full Text] [Related]
14. Metabolism of the failing heart. Katz AM Cardioscience; 1993 Dec; 4(4):199-203. PubMed ID: 8298061 [TBL] [Abstract][Full Text] [Related]
15. Metabolic remodelling of the failing heart: beneficial or detrimental? van Bilsen M; van Nieuwenhoven FA; van der Vusse GJ Cardiovasc Res; 2009 Feb; 81(3):420-8. PubMed ID: 18854380 [TBL] [Abstract][Full Text] [Related]
16. The myofilament force-calcium relationship as a target for positive inotropic therapy in congestive heart failure. MacGowan GA Cardiovasc Drugs Ther; 2005 May; 19(3):203-10. PubMed ID: 16142598 [TBL] [Abstract][Full Text] [Related]
17. [Pathophysiology of the "hibernating" myocardium]. Schulz R; Heusch G Z Kardiol; 1995; 84 Suppl 4():91-100. PubMed ID: 8585279 [TBL] [Abstract][Full Text] [Related]
18. Effects of amrinone on myocardial energetics in severe congestive heart failure. Baim DS Am J Cardiol; 1985 Jul; 56(3):16B-18B. PubMed ID: 3161318 [TBL] [Abstract][Full Text] [Related]
19. Inotropic therapy for the failing myocardium. Shipley JB; Hess ML Clin Cardiol; 1995 Nov; 18(11):615-9. PubMed ID: 8590529 [TBL] [Abstract][Full Text] [Related]
20. Left ventricular geometry, myocardial function and energetics of the dilated left ventricle. Influence of vasodilators and positive inotropic substances. Holubarsch C; Hasenfuss G; Thierfelder L; Just H Herz; 1991 Sep; 16 Spec No 1():298-303. PubMed ID: 1820296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]